Q1 Earnings Estimate for NTLA Issued By William Blair

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Analysts at William Blair issued their Q1 2026 earnings estimates for shares of Intellia Therapeutics in a research report issued on Wednesday, March 26th. William Blair analyst M. Minter anticipates that the company will post earnings per share of ($1.12) for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. William Blair also issued estimates for Intellia Therapeutics’ Q3 2026 earnings at ($1.28) EPS and Q4 2026 earnings at ($1.35) EPS.

NTLA has been the topic of a number of other reports. Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $60.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Truist Financial dropped their price target on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Chardan Capital lowered their target price on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Finally, Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $56.00 to $11.00 in a report on Monday, January 27th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $37.56.

Intellia Therapeutics Stock Down 3.9 %

NTLA opened at $8.07 on Thursday. The company has a market cap of $835.38 million, a price-to-earnings ratio of -1.48 and a beta of 1.97. The firm’s fifty day simple moving average is $9.98 and its two-hundred day simple moving average is $13.81. Intellia Therapeutics has a 52-week low of $8.03 and a 52-week high of $28.18.

Insider Activity

In related news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders have sold 29,000 shares of company stock valued at $352,551. 3.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Intellia Therapeutics in the 4th quarter valued at approximately $43,177,000. Voloridge Investment Management LLC lifted its stake in Intellia Therapeutics by 226.8% during the fourth quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock worth $17,805,000 after purchasing an additional 1,059,751 shares in the last quarter. Contrarius Group Holdings Ltd purchased a new position in shares of Intellia Therapeutics during the fourth quarter worth $11,798,000. Two Sigma Advisers LP grew its stake in shares of Intellia Therapeutics by 94.5% in the fourth quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock valued at $23,300,000 after buying an additional 970,700 shares in the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of Intellia Therapeutics by 88.1% in the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company’s stock valued at $21,498,000 after buying an additional 863,363 shares during the period. Hedge funds and other institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.